A SYSTEMATIC MAPPING REVIEW OF IN-VITRO AND IN-VIVO EVIDENCES EXPLORING THE ROLE OF STRAIN-SPECIFIC PROBIOTIC BIFIDOBACTERIUM LONGUM W11
Abstract
The gut microbiome has a significant role in overall well-being. Various probiotics are currently used for the improvement of the gut microbiome; the current scoping review aimed to critically examine the effectiveness of Bifidobacterium longum W11 in healthy and disease states. A thorough search of the literature was done in three scientific databases (PubMed, ScienceDirect, and Google Scholar) to identify and retrieve in-vitro, pre-clinical, and clinical evidence that evaluated the effect of B. longum W11 probiotic. Two independent reviewers identified and screened articles, published from 2000 to 2023 from the databases. Data from eligible studies were extracted, compiled, critically evaluated for scientific strength, and presented in this scoping review. Initially, 663 articles were identified and after a complete screening and evaluation process, twenty-one articles (eight in-vitro and animal studies; thirteen clinical studies) were included. Pre-clinical data suggest that B. longum W11 can withstand the severe gastrointestinal environment and colonize the intestinal epithelial cells to a significant degree. Due to the presence of a specific EPS cluster gene, B. longum W11 is capable of producing unique exopolysaccharides that might be responsible for the adhesion and functional capabilities of B. longum W11. Additionally, the specific mutation in the rpoB gene confers the B. longum W11 resistance to all rifamycin derivatives (including rifaximin). Clinical studies involving individuals with constipation and irritable bowel syndrome have shown that B. longum W11 supplementation significantly improves the overall quality of life and reduces the severity of symptoms. Furthermore, B. longum W11 was found to be effective in minimal hepatic encephalopathy and active celiac disease conditions. Due to the antibiotic resistance, the simultaneous use of rifaximin and B. longum W11 in patients with uncomplicated diverticular disease condition resulted in greater improvement in various symptoms compared to rifaximin supplementation alone. These data suggest that B. longum W11 is a potential probiotic that can be administered along with antibiotics in various gastrointestinal disease conditions. This evidence suggests that B. longum W11 is a promising probiotic with potential applications in various functional and inflammatory GI-related complications. Further clinical studies and stringent systematic reviews are needed to strengthen the outcomes of the current study.
Keywords:
Bifidobacterium longum W11, Irritable Bowel Syndrome, Nonalcoholic steatohepatitis, Minimal Hepatic Encephalopathy, Constipation, RifaximinDOI
https://doi.org/10.25004/IJPSDR.2024.160117References
Thursby E, Juge N. Introduction to the human gut microbiota. Biochem J.2017;474(11):1823–36.
DeGruttola AK, Low D, Mizoguchi A, Mizoguchi E. Current Understanding of Dysbiosis in Disease in Human and Animal Models. Inflamm Bowel Dis. 2016;22(5):1137–50.
Appanna V. Dysbiosis, Probiotics, and Prebiotics: In Diseases and Health. In: Appanna V, editor. Human Microbes - The Power Within. Singapore: Springer Nature Singapore Pte Ltd.; 2018. p. 81–122.
Fijan S. Microorganisms with claimed probiotic properties: an overview of recent literature. Int J Environ Res Public Health. 2014;11(5):4745–67.
Pierro F Di, Pane M. Bifidobacterium longum W11: Uniqueness and individual or combined clinical use in association with rifaximin. Clin Nutr ESPEN. 2021;42:15–21.
O’Callaghan A, Sinderen D van. Bifidobacteria and Their Role as Members of the Human Gut Microbiota. Front Microbiol. 2016;7:925.
Tojo R, Suárez A, Clemente MG, Reyes-Gavilán CG de los, Margolles A, Gueimonde M, et al. Intestinal microbiota in health and disease: role of bifidobacteria in gut homeostasis. World J Gastroenterol. 2014;20(41):15163–76.
Martínez-Martínez MI, Calabuig-Tolsá R, Cauli O. The effect of probiotics as a treatment for constipation in elderly people: A systematic review. Arch Gerontol Geriatr. 2017;71:142–9.
Peters MDJ, Godfrey CM, Khalil H, McInerney P, Parker D, Soares CB. Guidance for conducting systematic scoping reviews. Int J Evid Based Healthc. 2015;13(3):141–6.
Inturri R, Ventura M, Ruas-Madiedo P, Lugli GA, Blandino G. Complete Genome Sequence of Bifidobacterium longum W11 (LMG P-21586), Used as a Probiotic Strain. Genome Announc. 2017;5(10):e01659-16.
Izquierdo E, Medina M, Ennahar S, Marchioni E, Sanz Y. Resistance to simulated gastrointestinal conditions and adhesion to mucus as probiotic criteria for Bifidobacterium longum strains. Curr Microbiol. 2008;56(6):613–8.
Inturri R, Stivala A, Sinatra F, Morrone R, Blandino G. Scanning Electron Microscopy Observation of Adhesion Properties of Bifidobacterium longum W11 and Chromatographic Analysis of Its Exopolysaccaride. Food Nutr Sci. 2014;5(18):1787–92.
Lu Y, Han S, Zhang S, Wang K, Lv L, McClements DJ, et al. The role of probiotic exopolysaccharides in adhesion to mucin in different gastrointestinal conditions. Curr Res Food Sci. 2022;5:581–9.
Oerlemans MM, Akkerman R, Ferrari M, Walvoort MT, Vos P de. Benefits of bacteria-derived exopolysaccharides on gastrointestinal microbiota, immunity and health. J Funct Foods. 2021;76:104289.
Caselli M, Vaira G, Calo G, Papini F, Holton J, Vaira D. Structural bacterial molecules as potential candidates for an evolution of the classical concept of probiotics. Adv Nutr. 2011;2(5):372–6.
Hidalgo-Cantabrana C, Sánchez B, Milani C, Ventura M, Margolles A, Ruas-Madiedo P. Genomic overview and biological functions of exopolysaccharide biosynthesis in Bifidobacterium spp. Appl Environ Microbiol. 2014;80(1):9–18.
Inturri R, Molinaro A, Lorenzo F Di, Blandino G, Barbara Tomasello, Hidalgo-Cantabrana C, et al. Chemical and biological properties of the novel exopolysaccharide produced by a probiotic of Bifidobacterium longum. Carbohydr Polym. 2017;174:1172–80.
Medina M, Izquierdo E, Ennahar S, Sanz Y. Differential immunomodulatory properties of Bifidobacterium logum strains: relevance to probiotic selection and clinical applications. Clin Exp Immunol. 2007;150(3):531–8.
Inturri R, Mangano K, Santagati M, Intrieri M, Marco R Di, Blandino G. Immunomodulatory Effects of Bifidobacterium longum W11 Produced Exopolysaccharide on Cytokine Production. Curr Pharm Biotechnol. 2017;18(11):883–9.
Graziano T, Amoruso A, Nicola S, Deidda F, Allesina S, Pane M, et al. The Possible Innovative Use of Bifidobacterium longum W11 in Association With Rifaximin: A New Horizon for Combined Approach? J Clin Gastroenterol. 2016;50(Suppl 2):S153–6.
Amenta M, Cascio MT, Fiore P Di, Venturini I. Diet and chronic constipation. Benefits of oral supplementation with symbiotic zir fos (Bifidobacterium longum W11+ FOS Actilight). Vol. 77, Acta Bio-medica. 2006. p. 157–62.
Colecchia A, Vestito A, Rocca A La, Pasqui F, Nikiforaki A, Festi D, et al. Effect of a symbiotic preparation on the clinical manifestations of irritable bowel syndrome, constipation-variant. Results of an open, uncontrolled multicenter study. Minerva Gastroenterol Dietol. 2006;52(4):349–58.
Dughera L, Elia C, Navino M, Cisarò F, Group AS. Effects of symbiotic preparations on constipated irritable bowel syndrome symptoms. Acta Bio-medica. 2007;78(2):111–6.
Valdovinos-Díaz M, Abreu AA y, Frati-Munari A. Clinical experience with a synbiotic (Bifidobacterium longum AW11-Fos cc. Actilight) in the relieve of constipation and other digestive symptoms. Med interna México. 2017;33(4):476–86.
Saadi M, McCallum RW. Rifaximin in irritable bowel syndrome: rationale, evidence and clinical use. Ther Adv Chronic Dis. 2013;4(2):71–5.
Pimentel M, Lembo A, Chey WD, Zakko S, Ringel Y, Yu J, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364(1):22–32.
Li J, Zhu W, Liu W, Wu Y, Wu B. Rifaximin for Irritable Bowel Syndrome: A Meta-Analysis of Randomized Placebo-Controlled Trials. Medicine (Baltimore). 2016;95(4):e2534.
Fanigliulo L, Comparato G, Aragona G, Cavallaro L, Veronica Iori, Maino M, et al. Role of gut microflora and probiotic effects in the irritable bowel syndrome. Acta Bio-medica. 2006;77(2):85–9.
Polymeros D, Beintaris I, Gaglia A, Karamanolis G, Papanikolaou IS, Dimitriadis G, et al. Partially hydrolyzed guar gum accelerates colonic transit time and improves symptoms in adults with chronic constipation. Dig Dis Sci. 2014;59(9):2207–14.
Sarnelli G, Russo L, Giorgi F De, Efficie E, Esposito I, Atteo E, et al. Effects of oral supplementation with the symbiotic (bifidobacterium longum w11+ fos actilight) on IBS with constipation: a randomized, dose finding trial, versus fibers. Dig Liver Dis. 2008;40:S141.
Piano M Del, Ballarè M, Montino F, Marco Orsello, Garello E, Ferrari P, et al. Clinical experience with probiotics in the elderly on total enteral nutrition. J Clin Gastroenterol. 2004;38(6 Suppl):S111-114.
Stinton LM, Jayakumar S. Minimal hepatic encephalopathy. Can J Gastroenterol. 2013;27(10):572–4.
Zhang Z, Zhai H, Geng J, Yu R, Ren H, Fan H, et al. Large-scale survey of gut microbiota associated with MHE Via 16S rRNA-based pyrosequencing. Am J Gastroenterol. 2013;108(10):1601–11.
Malaguarnera M, Greco F, Barone G, Gargante MP, Malaguarnera M, Toscano MA. Bifidobacterium longum with fructo-oligosaccharide (FOS) treatment in minimal hepatic encephalopathy: a randomized, double-blind, placebo-controlled study. Dig Dis Sci. 2007;52(11):3259–65.
Wang J, He W, Tsai P-J, Chen P-H, Ye M, Guo J, et al. Mutual interaction between endoplasmic reticulum and mitochondria in nonalcoholic fatty liver disease. Lipids Health Dis. 2020;19(1):72.
Fang J, Yu C-H, Li X-J, Yao J-M, Fang Z-Y, Yoon S-H, et al. Gut dysbiosis in nonalcoholic fatty liver disease: pathogenesis, diagnosis, and therapeutic implications. Front Cell Infect Microbiol. 2022;12:997018.
Ben M Del, Polimeni L, Baratta F, Pastori D, Angelico F. The role of nutraceuticals for the treatment of non‐alcoholic fatty liver disease. Br J Clin Pharmacol. 2017;83(1):88–95.
Zhang C, Yang M. Current Options and Future Directions for NAFLD and NASH Treatment. Int J Mol Sci. 2021;22(14):7571.
Malaguarnera M, Vacante M, Antic T, Giordano M, Chisari G, Acquaviva R, et al. Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis. Dig Dis Sci. 2012;57(2):545–53.
Caio G, Volta U, Sapone A, Leffler DA, Giorgio R De, Catassi C, et al. Celiac disease: a comprehensive current review. BMC Med. 2019;17(1):142.
Copaci I, Chiriac G, Micu L. The effects of a prebiotic/probiotic combination in active celiac disease. In: Celiac Disease and Other Small Bowel Disorders. Amsterdam (The Netherlands): Falk Symposium 193; 2014. p. 20.
Maconi G. Diagnosis of symptomatic uncomplicated diverticular disease and the role of Rifaximin in management. Acta Bio-medica. 2017;88(1):25–32.
Pierro F Di, Bertuccioli A, Pane M, Ivaldi L. Effects of rifaximin-resistant Bifidobacterium longum W11 in subjects with symptomatic uncomplicated diverticular disease treated with rifaximin. Minerva Gastroenterol Dietol. 2019;65(4):259–64.
Published
Abstract Display: 592 
PDF Downloads: 530 
